Sort   by:  
 Page size 
ProteomicsInteractomic characterization of ESR1 mutant cells
Three quarters of all breast cancer cases express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastatic breast cancers, in particular to aromatase inhibitors....
ORGANISM(S): Homo sapiens (Human) 
2024-03-26 | PXD032404 | Pride
Esr1 mutation Breast cancer 
ProteomicsProteomic characterization of ESR1 mutant cells
Three quarters of all breast cancer cases express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastatic breast cancers, in particular to aromatase inhibitors....
ORGANISM(S): Homo sapiens (Human) 
2024-03-26 | PXD032369 | Pride
Esr1 mutation Breast cancer 
GenomicsTargeting ESR1 mutation-induced transcriptional addiction with BET inhibition
Targeting ESR1 mutation-induced transcriptional addiction with BET inhibition
PRJNA849568 | ENA
TranscriptomicsXenografting of advanced stage breast cancer preserves the genomic and clonal architecture and captures luminal tumors harboring mutations and gene rearrangements in ESR1
End-stage breast cancers are clonally heterogeneous and harbor many poorly-understood treatment resistance mechanisms. We therefore established multiple Patient-Derived-Xenograft (PDX) models to study genomic events driving advanced disease. Comparative whole-genome sequencing of paired primary tu...
ORGANISM(S): Homo sapiens 
2013-12-22 | E-GEOD-46604 | biostudies-arrayexpress
TranscriptomicsModeling the ESR1 tyrosine 537 mutation with CRISPR-Cas9 for mechanistic studies and evaluation of therapeutic approaches for metastatic breast cancer [RNA-Seq]
Estrogen receptor-α (ERα) is an important driver of breast cancer and is the target for hormonal therapies, anti-estrogens and drugs that limit estrogen biosynthesis (aromatase inhibitors). Mutations in the ESR1 gene identified in metastatic breast cancer provide a potential mechanism for acquired...
ORGANISM(S): Homo sapiens 
2016-10-25 | E-GEOD-78285 | biostudies-arrayexpress
GenomicsModeling the ESR1 tyrosine 537 mutation with CRISPR-Cas9 for mechanistic studies and evaluation of therapeutic approaches for metastatic breast cancer [ChIP-Seq]
Estrogen receptor-α (ERα) is an important driver of breast cancer and is the target for hormonal therapies, anti-estrogens and drugs that limit estrogen biosynthesis (aromatase inhibitors). Mutations in the ESR1 gene identified in metastatic breast cancer provide a potential mechanism for acquired...
ORGANISM(S): Homo sapiens 
2016-10-25 | E-GEOD-78284 | biostudies-arrayexpress
TranscriptomicsTargeting ESR1 mutation-induced transcriptional addiction with BET inhibition
We investigated the therapeutic potential of BET inhibition to target ESR1 mutation-induced “transcriptional addiction” in ER-positive breast cancer. Our studies show that ESR1 mutant (Y537S and D538G) cells activate unique transcriptional programs that are targeted by OTX015, a BET inhibitor
ORGANISM(S): Homo sapiens 
2022-06-18 | GSE206185 | GEO
GenomicsMCF-7 cells long-term treated with Fulv plus Abema acquired ESR1 Y537S mutation and exhibited defective RSR and DDR
MCF-7 cells long-term treated with Fulv plus Abema acquired ESR1 Y537S mutation and exhibited defective RSR and DDR
PRJNA1390673 | ENA
GenomicsMCF-7 ESR1 drug response scRNA
MCF-7 ESR1 drug response scRNA
PRJNA1076489 | ENA
GenomicsMCF-7 ESR1 drug response bulk RNA
MCF-7 ESR1 drug response bulk RNA
PRJNA1076488 | ENA
Sort   by:  
 Page size